Rivaroxaban (Xarelto®) : efficacité et tolérance
- 31 December 2008
- journal article
- research article
- Published by Elsevier BV in Annales Françaises dʼAnesthésie et de Réanimation
- Vol. 27, S22-S27
- https://doi.org/10.1016/s0750-7658(08)75143-8
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialThe Lancet, 2008
- Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategiesAnaesthesia, 2007
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- Anticoagulants and Transaminase ElevationCirculation, 2006
- Severe Neurological Complications after Central Neuraxial Blockades in Sweden 1990–1999Anesthesiology, 2004
- Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End PointsChest, 2004